ValiRx plc (AIM:VAL)

Market Cap	1.98M +125.1%
Revenue (ttm)	32.67K -34.4%
Net Income	-2.14M
EPS	-0.00
Shares Out	1.32B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,473,163
Open	0.1400
Previous Close	0.1450
Day's Range	0.1300 - 0.1500
52-Week Range	0.1200 - 0.4800
Beta	-0.41
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 16, 2026

About ValiRx

ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical trial for the treatment of endometriosis. It is also involved in the dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 11
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: VAL

Financial Performance

In 2025, ValiRx's revenue was 31,372, a decrease of -36.97% compared to the previous year's 49,775. Losses were -2.23 million, 16.5% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 6, 2026

Data Sources Report a data error